Company
Company description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Quick Presentation Filters
Related Companies

Filter

      Loading ...

      Loading ...

      Loading ...

Filter

      Loading ...

      Loading ...

      Loading ...

Presentations (4)
Investor Presentation
January 2024
41 slides
Investor Presentation
November 2023
56 slides
Investor Presentation
August 2023
56 slides
IPO
July 2021
46 slides
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io